Kunihiko Kobayashi

8PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Historical, comparative and typological linguisticsRespiratory diseasesTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 09, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim

|Jun 27, 2025
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.

Yuhei Kurata, Atsuto Mouri, Hisao Imai

|Apr 13, 2024
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.

Atsuto Mouri, Satoshi Watanabe, Takaaki Tokito

|Apr 03, 2024
Reply to Y. Yu et al.

Pasi A Jänne, David Planchard, Kunihiko Kobayashi

|Jan 23, 2024
Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study.

Keita Kawakado, Yukari Tsubata, Takamasa Hotta

|Dec 02, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.

Pasi A Jänne, David Planchard, Kunihiko Kobayashi

Pageof 2

Frequent Collaborators

4 joint publications

Hisao Imai

3 joint publications

Hiroshi Kagamu

3 joint publications

Kyoichi Kaira

2 joint publications

Satoshi Yamasaki